Global Pharmacogenomics Technology (Theranostics & CDx) Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 266099
  • calendar_today Published On: Jan, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Pharmacogenomics Technology (Theranostics & CDx) market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Pharmacogenomics Technology (Theranostics & CDx) market size is estimated to be worth US$ 9869.6 million in 2021 and is forecast to a readjusted size of USD 24800 million by 2028 with a CAGR of 14.1% during review period. Tumor accounting for % of the Pharmacogenomics Technology (Theranostics & CDx) global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Instrument segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Pharmacogenomics Technology (Theranostics & CDx) include Illumina, Roche, Agilent, Abbott, and Thermofisher, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Pharmacogenomics Technology (Theranostics & CDx) market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Instrument

Reagents and Consumables

Others

Market segment by Application, can be divided into

Tumor

Diabetes

Mental Diseases

Cardiovascular Diseases

Others

Market segment by players, this report covers

Illumina

Roche

Agilent

Abbott

Thermofisher

Qiagen

Guardant Health

MGI Tech Co., Ltd.

Amoydx Biology

Genomics

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Pharmacogenomics Technology (Theranostics & CDx) product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Pharmacogenomics Technology (Theranostics & CDx), with revenue, gross margin and global market share of Pharmacogenomics Technology (Theranostics & CDx) from 2019 to 2022.

Chapter 3, the Pharmacogenomics Technology (Theranostics & CDx) competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Pharmacogenomics Technology (Theranostics & CDx) market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Pharmacogenomics Technology (Theranostics & CDx) research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Pharmacogenomics Technology (Theranostics & CDx)

1.2 Classification of Pharmacogenomics Technology (Theranostics & CDx) by Type

1.2.1 Overview: Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type in 2021

1.2.3 Instrument

1.2.4 Reagents and Consumables

1.2.5 Others

1.3 Global Pharmacogenomics Technology (Theranostics & CDx) Market by Application

1.3.1 Overview: Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Tumor

1.3.3 Diabetes

1.3.4 Mental Diseases

1.3.5 Cardiovascular Diseases

1.3.6 Others

1.4 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size & Forecast

1.5 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast by Region

1.5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region, (2017-2022)

1.5.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2017-2028)

1.5.4 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2017-2028)

1.5.6 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Pharmacogenomics Technology (Theranostics & CDx) Market Drivers

1.6.2 Pharmacogenomics Technology (Theranostics & CDx) Market Restraints

1.6.3 Pharmacogenomics Technology (Theranostics & CDx) Trends Analysis

2 Company Profiles

2.1 Illumina

2.1.1 Illumina Details

2.1.2 Illumina Major Business

2.1.3 Illumina Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.1.4 Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Illumina Recent Developments and Future Plans

2.2 Roche

2.2.1 Roche Details

2.2.2 Roche Major Business

2.2.3 Roche Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.2.4 Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Roche Recent Developments and Future Plans

2.3 Agilent

2.3.1 Agilent Details

2.3.2 Agilent Major Business

2.3.3 Agilent Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.3.4 Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Agilent Recent Developments and Future Plans

2.4 Abbott

2.4.1 Abbott Details

2.4.2 Abbott Major Business

2.4.3 Abbott Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.4.4 Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Abbott Recent Developments and Future Plans

2.5 Thermofisher

2.5.1 Thermofisher Details

2.5.2 Thermofisher Major Business

2.5.3 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.5.4 Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Thermofisher Recent Developments and Future Plans

2.6 Qiagen

2.6.1 Qiagen Details

2.6.2 Qiagen Major Business

2.6.3 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.6.4 Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Qiagen Recent Developments and Future Plans

2.7 Guardant Health

2.7.1 Guardant Health Details

2.7.2 Guardant Health Major Business

2.7.3 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.7.4 Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Guardant Health Recent Developments and Future Plans

2.8 MGI Tech Co., Ltd.

2.8.1 MGI Tech Co., Ltd. Details

2.8.2 MGI Tech Co., Ltd. Major Business

2.8.3 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.8.4 MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 MGI Tech Co., Ltd. Recent Developments and Future Plans

2.9 Amoydx Biology

2.9.1 Amoydx Biology Details

2.9.2 Amoydx Biology Major Business

2.9.3 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.9.4 Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Amoydx Biology Recent Developments and Future Plans

2.10 Genomics

2.10.1 Genomics Details

2.10.2 Genomics Major Business

2.10.3 Genomics Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

2.10.4 Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Genomics Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share in 2021

3.2.2 Top 10 Pharmacogenomics Technology (Theranostics & CDx) Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Pharmacogenomics Technology (Theranostics & CDx) Players Head Office, Products and Services Provided

3.4 Pharmacogenomics Technology (Theranostics & CDx) Mergers & Acquisitions

3.5 Pharmacogenomics Technology (Theranostics & CDx) New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue and Market Share by Type (2017-2022)

4.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application (2017-2022)

5.2 Global Pharmacogenomics Technology (Theranostics & CDx) Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2028)

6.2 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2028)

6.3 North America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country

6.3.1 North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2017-2028)

6.3.2 United States Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

6.3.3 Canada Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

6.3.4 Mexico Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2028)

7.2 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2028)

7.3 Europe Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country

7.3.1 Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2017-2028)

7.3.2 Germany Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

7.3.3 France Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

7.3.5 Russia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

7.3.6 Italy Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2028)

8.2 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2028)

8.3 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Market Size by Region

8.3.1 Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (2017-2028)

8.3.2 China Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

8.3.3 Japan Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

8.3.4 South Korea Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

8.3.5 India Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

8.3.7 Australia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2028)

9.2 South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2028)

9.3 South America Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country

9.3.1 South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2017-2028)

9.3.2 Brazil Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

9.3.3 Argentina Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2028)

10.2 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2028)

10.3 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Market Size by Country

10.3.1 Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2017-2028)

10.3.2 Turkey Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

10.3.4 UAE Pharmacogenomics Technology (Theranostics & CDx) Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Pharmacogenomics Technology (Theranostics & CDx) Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) by Region (2017-2022)

Table 5. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Region (2023-2028)

Table 6. Illumina Corporate Information, Head Office, and Major Competitors

Table 7. Illumina Major Business

Table 8. Illumina Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 9. Illumina Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Roche Corporate Information, Head Office, and Major Competitors

Table 11. Roche Major Business

Table 12. Roche Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 13. Roche Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Agilent Corporate Information, Head Office, and Major Competitors

Table 15. Agilent Major Business

Table 16. Agilent Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 17. Agilent Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Abbott Corporate Information, Head Office, and Major Competitors

Table 19. Abbott Major Business

Table 20. Abbott Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 21. Abbott Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Thermofisher Corporate Information, Head Office, and Major Competitors

Table 23. Thermofisher Major Business

Table 24. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 25. Thermofisher Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Qiagen Corporate Information, Head Office, and Major Competitors

Table 27. Qiagen Major Business

Table 28. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 29. Qiagen Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Guardant Health Corporate Information, Head Office, and Major Competitors

Table 31. Guardant Health Major Business

Table 32. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 33. Guardant Health Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. MGI Tech Co., Ltd. Corporate Information, Head Office, and Major Competitors

Table 35. MGI Tech Co., Ltd. Major Business

Table 36. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 37. MGI Tech Co., Ltd. Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Amoydx Biology Corporate Information, Head Office, and Major Competitors

Table 39. Amoydx Biology Major Business

Table 40. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 41. Amoydx Biology Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Genomics Corporate Information, Head Office, and Major Competitors

Table 43. Genomics Major Business

Table 44. Genomics Pharmacogenomics Technology (Theranostics & CDx) Product and Solutions

Table 45. Genomics Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 47. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 48. Breakdown of Pharmacogenomics Technology (Theranostics & CDx) by Company Type (Tier 1, Tier 2 and Tier 3)

Table 49. Pharmacogenomics Technology (Theranostics & CDx) Players Head Office, Products and Services Provided

Table 50. Pharmacogenomics Technology (Theranostics & CDx) Mergers & Acquisitions in the Past Five Years

Table 51. Pharmacogenomics Technology (Theranostics & CDx) New Entrants and Expansion Plans

Table 52. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) by Type (2017-2022)

Table 53. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type (2017-2022)

Table 54. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Forecast by Type (2023-2028)

Table 55. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2022)

Table 56. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Forecast by Application (2023-2028)

Table 57. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2022) & (USD Million)

Table 58. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2023-2028) & (USD Million)

Table 59. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2022) & (USD Million)

Table 60. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2023-2028) & (USD Million)

Table 61. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2017-2022) & (USD Million)

Table 62. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2023-2028) & (USD Million)

Table 63. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2022) & (USD Million)

Table 64. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2023-2028) & (USD Million)

Table 65. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2022) & (USD Million)

Table 66. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2023-2028) & (USD Million)

Table 67. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2017-2022) & (USD Million)

Table 68. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2023-2028) & (USD Million)

Table 69. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2022) & (USD Million)

Table 70. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2023-2028) & (USD Million)

Table 71. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2022) & (USD Million)

Table 72. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2023-2028) & (USD Million)

Table 73. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (2017-2022) & (USD Million)

Table 74. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue by Region (2023-2028) & (USD Million)

Table 75. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2022) & (USD Million)

Table 76. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2023-2028) & (USD Million)

Table 77. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2022) & (USD Million)

Table 78. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2023-2028) & (USD Million)

Table 79. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2017-2022) & (USD Million)

Table 80. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2023-2028) & (USD Million)

Table 81. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2017-2022) & (USD Million)

Table 82. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Type (2023-2028) & (USD Million)

Table 83. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2017-2022) & (USD Million)

Table 84. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Application (2023-2028) & (USD Million)

Table 85. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2017-2022) & (USD Million)

Table 86. Middle East & Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Pharmacogenomics Technology (Theranostics & CDx) Picture

Figure 2. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Type in 2021

Figure 3. Instrument

Figure 4. Reagents and Consumables

Figure 5. Others

Figure 6. Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Application in 2021

Figure 7. Tumor Picture

Figure 8. Diabetes Picture

Figure 9. Mental Diseases Picture

Figure 10. Cardiovascular Diseases Picture

Figure 11. Others Picture

Figure 12. Global Pharmacogenomics Technology (Theranostics & CDx) Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 13. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue and Forecast (2017-2028) & (USD Million)

Figure 14. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Region (2017-2028)

Figure 15. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Region in 2021

Figure 16. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Pharmacogenomics Technology (Theranostics & CDx) Market Drivers

Figure 22. Pharmacogenomics Technology (Theranostics & CDx) Market Restraints

Figure 23. Pharmacogenomics Technology (Theranostics & CDx) Market Trends

Figure 24. Illumina Recent Developments and Future Plans

Figure 25. Roche Recent Developments and Future Plans

Figure 26. Agilent Recent Developments and Future Plans

Figure 27. Abbott Recent Developments and Future Plans

Figure 28. Thermofisher Recent Developments and Future Plans

Figure 29. Qiagen Recent Developments and Future Plans

Figure 30. Guardant Health Recent Developments and Future Plans

Figure 31. MGI Tech Co., Ltd. Recent Developments and Future Plans

Figure 32. Amoydx Biology Recent Developments and Future Plans

Figure 33. Genomics Recent Developments and Future Plans

Figure 34. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Players in 2021

Figure 35. Pharmacogenomics Technology (Theranostics & CDx) Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 36. Global Top 3 Players Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share in 2021

Figure 37. Global Top 10 Players Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share in 2021

Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 39. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Type in 2021

Figure 40. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Type (2023-2028)

Figure 41. Global Pharmacogenomics Technology (Theranostics & CDx) Revenue Share by Application in 2021

Figure 42. Global Pharmacogenomics Technology (Theranostics & CDx) Market Share Forecast by Application (2023-2028)

Figure 43. North America Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2017-2028)

Figure 44. North America Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2017-2028)

Figure 45. North America Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Country (2017-2028)

Figure 46. United States Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Canada Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Mexico Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Europe Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2017-2028)

Figure 50. Europe Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2017-2028)

Figure 51. Europe Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Country (2017-2028)

Figure 52. Germany Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. France Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. United Kingdom Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Russia Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Italy Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2017-2028)

Figure 58. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2017-2028)

Figure 59. Asia-Pacific Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Region (2017-2028)

Figure 60. China Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Japan Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. South Korea Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. India Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Southeast Asia Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Australia Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. South America Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2017-2028)

Figure 67. South America Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2017-2028)

Figure 68. South America Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Country (2017-2028)

Figure 69. Brazil Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Argentina Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Type (2017-2028)

Figure 72. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Sales Market Share by Application (2017-2028)

Figure 73. Middle East and Africa Pharmacogenomics Technology (Theranostics & CDx) Revenue Market Share by Country (2017-2028)

Figure 74. Turkey Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Saudi Arabia Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. UAE Pharmacogenomics Technology (Theranostics & CDx) Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Methodology

Figure 78. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz